Trial Profile
Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors AstraZeneca
- 29 Jul 2022 Status changed from active, no longer recruiting to completed.
- 25 May 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 1 to 4 and drug form includes capsule as well as tablet.
- 26 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.